Aelis Farma Announces Positive Results From Its Safety Trials in Healthy Volunteers and the Authorization to Start the First Trial in People with Down Syndrome with AEF0217, its Drug Candidate for the Treatment of Cognitive Disorders

BORDEAUX, France–(BUSINESS WIRE)–Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS, PEA-PME eligible) (Paris: AELIS), a clinical stage biopharmaceutical company specializing in the development of treatments for brain diseases, announces…